Xponance’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$8.41M Buy
105,038
+16,908
+19% +$1.39M 0.06% 248
2025
Q4
$7.51M Buy
88,130
+5,005
+6% +$411K 0.06% 250
2025
Q3
$6.46M Sell
83,125
-3,659
-4% -$286K 0.05% 276
2025
Q2
$6.79M Sell
86,784
-7,934
-8% -$592K 0.06% 261
2025
Q1
$6.87M Sell
94,718
-370
-0.4% -$26.5K 0.07% 239
2024
Q4
$7.04M Buy
95,088
+1,675
+2% +$117K 0.06% 232
2024
Q3
$6.16M Buy
93,413
+1,120
+1% +$81.4K 0.06% 250
2024
Q2
$8.53M Sell
92,293
-46,106
-33% -$4.08M 0.09% 175
2024
Q1
$13.2M Sell
138,399
-578
-0.4% -$48.6K 0.14% 127
2023
Q4
$10.6M Sell
138,977
-2,186
-2% -$152K 0.13% 135
2023
Q3
$9.78M Buy
141,163
+2,273
+2% +$183K 0.13% 131
2023
Q2
$13.1M Sell
138,890
-387
-0.3% -$33.6K 0.17% 101
2023
Q1
$11.5M Buy
139,277
+2,379
+2% +$187K 0.17% 114
2022
Q4
$10.2M Buy
136,898
+9,334
+7% +$719K 0.17% 117
2022
Q3
$10.5M Buy
127,564
+2,265
+2% +$218K 0.2% 93
2022
Q2
$11.9M Sell
125,299
-10,586
-8% -$1.1M 0.24% 72
2022
Q1
$16M Buy
135,885
+1,395
+1% +$156K 0.27% 70
2021
Q4
$17.4M Buy
134,490
+9,052
+7% +$1.06M 0.27% 63
2021
Q3
$14.2M Sell
125,438
-2,995
-2% -$342K 0.27% 71
2021
Q2
$13.3M Sell
128,433
-4,270
-3% -$402K 0.24% 72
2021
Q1
$11.1M Buy
132,703
+41,596
+46% +$3.52M 0.24% 79
2020
Q4
$8.31M Sell
91,107
-39,682
-30% -$3.29M 0.18% 100
2020
Q3
$10.4M Sell
130,789
-8,509
-6% -$664K 0.26% 73
2020
Q2
$9.63M Buy
+139,298
New +$9.9M 0.25% 85

Other funds holding EW

Xponance's EW Position: Q1 2026 in Review

Xponance increased its Edwards Lifesciences (EW) stake by 19% in Q1 2026, buying an estimated $1.39M and bringing the position to 105,038 shares worth $8.41M. The position accounts for 0.06% of the portfolio, ranked #248.

Xponance first reported a position in EW in Q2 2020 and has held it in 24 quarters since. The position peaked at $17.4M in Q4 2021. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.

  • Xponance held 105,038 shares of Edwards Lifesciences worth $8.41M as of Q1 2026.
  • Xponance bought 16,908 Edwards Lifesciences shares in Q1 2026, an estimated $1.39M.
  • Edwards Lifesciences made up 0.06% of Xponance's portfolio in Q1 2026, its #248 holding.
  • Xponance first reported a position in Edwards Lifesciences in Q2 2020 and has held it in 24 quarters since.
  • Xponance's Edwards Lifesciences position peaked at $17.4M in Q4 2021.
  • 1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on Xponance's 13F filing for Q1 2026, filed 13 May 2026.